Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses results from an 8 year follow-up of the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in 5102 women with HER2-postive early-stage breast cancer. For more coverage from SABCS, visit www.onclive.com